Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib, Firsocostat, Cilofexor, and Combinations in Subjects With Bridging (F3) Fibrosis or Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)

Next Previous
Trial Profile

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib, Firsocostat, Cilofexor, and Combinations in Subjects With Bridging (F3) Fibrosis or Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 21 May 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cilofexor (Primary) ; Firsocostat (Primary) ; Selonsertib (Primary)
  • Indications Fibrosis; Liver cirrhosis; Non-alcoholic steatohepatitis
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Acronyms ATLAS
  • Sponsors Gilead Sciences

    • Most Recent Events

    • 11 Apr 2019 According to a Gilead Sciences media release,the company will present an analysis of screening data from from the study demonstrating the use of currently available noninvasive tests (NITs) can accurately identify patients with advanced fibrosis due to NASH and potentially reduce the need for liver biopsy.
    • 11 Apr 2019 Results (n=20) presented in a Gilead Sciences media release.
    • 11 Feb 2019 According to a Gilead Sciences media release, the company now await the upcoming results from this study later this year.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top